Analysts say Darzalex sales prognosis could be too cautious
Analysts from both US-based Jefferies and Danish bank Sydbank say that the sales forecast for Johnson & Johnson's drug Darzalex, which the company obtained through a licensing agreement with Genmab, is a tad too conservative, perhaps signaling a potential upgrade.
BY MARKEWIRE, TRANSLATED BY DANIEL PEDERSEN
The sales of Darzalex have exceeded expectations in the third quarter of the year, surpassing net sales expectations by more than DKK 850 million.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab sales of Darzalex exceed expectations in Q3
For subscribers
Janssen had better Darzalex sales than expected in Q1
For subscribers
